In late September 2016, Lior Gantz and I turned extremely bullish on biotech stocks.
As we thought Donald Trump had a real shot at winning the presidency, we profiled our debut biotech stock, and it has been a big winner for us.
His policies have cleared the way for businesses to advance with more assurance.
Within biotech, the personalized medicine segment is, by far, the fastest-growing niche, and the reason is that in a few years, it will be the only way patients will want to be treated.
Our top biotechnology company is armed with fully protected issued and pending patents across multiple nations and continents, it is led by top echelon scientific and business entrepreneurs, and it is already attracting the likes of pharmaceutical blue chip giants Johnson & Johnson and Merck to take interest.
Major advancements in the marijuana industry include the formation of exchange platforms where it will be traded, agricultural technology that will enable refined crops, modern greenhouses, and smarter manufacturing procedures.
Get the full report on the perfect Trump Stock and be positioned early in what could be a 2017 Top-Gainer.